{"1": ["1. Definitions", {"1": ["1.1 Affiliate 7", {}], "2": ["1.2 Agreement 7", {}], "3": ["1.3 Agreement Term 7", {}], "4": ["1.4 [...***...] ctDNA [...***...] 7", {}], "5": ["1.5 Applicable Law 7", {}], "6": ["1.6 Approved Assay 7", {}], "7": ["1.7 Background IP 7", {}], "8": ["1.8 Business Day 8", {}], "9": ["1.9 Calendar Half 8", {}], "10": ["1.10 Calendar Quarter 8", {}], "11": ["1.11 Calendar Year 8", {}], "12": ["1.12 CDx 8", {}], "13": ["1.13 CDx Development Program 8", {}], "14": ["1.14 CLIA 8", {}], "15": ["1.15 Clinical Study 9", {}], "16": ["1.16 Commercially Reasonable Efforts 9", {}], "17": ["1.17 Confidential Information 9", {}], "18": ["1.18 Control 9", {}], "19": ["1.19 Cover 10", {}], "20": ["1.20 ctDNA 10", {}], "21": ["1.21 ctDNA Assay 10", {}], "22": ["1.22 ctDNA Platform 10", {}], "23": ["1.23 ctDNA Platform Development Program 10", {}], "24": ["1.24 ctDNA Working Group 10", {}], "25": ["1.25 Data Security Breach 10", {}], "26": ["1.26 Effective Date 10", {}], "27": ["1.27 Excepted Activities 11", {}], "28": ["1.28 Excluded Patent Rights 11", {}], "29": ["1.29 FDA 11", {}], "30": ["1.30 FDCA 11", {}], "31": ["1.31 FMI Background IP Patent Rights 11", {}], "32": ["1.32 FMI Decisions 11", {}], "33": ["1.33 FMI Development Costs 11", {}], "34": ["1.34 FMI Know-How 11", {}], "35": ["1.35 FMI Foreground Patent Rights 12", {}], "36": ["1.36 FTE 12", {}], "37": ["1.37 FTE Rate 12", {}], "38": ["1.38 Handle 12", {}], "39": ["1.39 HSR 12", {}], "40": ["1.40 Immunotherapy Testing Platform Development Program 12", {}], "41": ["1.41 Immuno-Platform Working Group 12", {}], "42": ["1.42 Initiation 12", {}], "43": ["1.43 Insolvency Event 12", {}], "44": ["1.44 Invention 13", {}], "45": ["1.45 IUO 13", {}], "46": ["1.46 JMC 13", {}], "47": ["1.47 JOC 13", {}], "48": ["1.48 Joint Know-How 13", {}], "49": ["1.49 Joint Patent Rights 13", {}], "50": ["1.50 JOT 13", {}], "51": ["1.51 JRDC 13", {}], "52": ["1.52 Know-How 13", {}], "53": ["1.53 Molecular Information Platform Program 13", {}], "54": ["1.54 Molecular Information Platform Working Group 14", {}], "55": ["1.55 Party 14", {}], "56": ["1.56 Patent Rights 14", {}], "57": ["1.57 Performance Specifications 14", {}], "58": ["1.58 Personal Data 14", {}], "59": ["1.59 Phase I Study 14", {}], "60": ["1.60 Phase II Study 14", {}], "61": ["1.61 Phase III Study 14", {}], "62": ["1.62 PMA 15", {}], "63": ["1.63 Quality Standards 15", {}], "64": ["1.64 R&D Plan 15", {}], "65": ["1.65 Regulatory Approval 15", {}], "66": ["1.66 Regulatory Authority 15", {}], "67": ["1.67 Roche Background IP Patent Rights 15", {}], "68": ["1.68 Roche Group 15", {}], "69": ["1.69 Roche Know-How 15", {}], "70": ["1.70 Roche Foreground Patent Rights 15", {}], "71": ["1.71 ROW Territory 15", {}], "72": ["1.72 RUO 15", {}], "73": ["1.73 Study Data 16", {}], "74": ["1.74 Sublicensee 16", {}], "75": ["1.75 Territory 16", {}], "76": ["1.76 Third Party 16", {}], "77": ["1.77 US 16", {}], "78": ["1.78 US$ 16", {}], "79": ["1.79 Work Stream 16", {}], "80": ["1.80 Additional Definitions 16", {}]}], "2": ["2. Grant of License", {"1": ["2.1 Licenses 18", {}], "2": ["2.2 Sublicense 20", {}], "3": ["2.3 Right to Subcontract 20", {}]}], "3": ["3. Research and Development Collaboration", {"1": ["3.1 Molecular Information Platform Program 20", {}], "2": ["3.2 Immunotherapy Testing Platform Development Program 23", {}], "3": ["3.3 ctDNA Platform Development Program 25", {}], "4": ["3.4 CDx Development Program 27", {}], "5": ["3.5 Samples, Handling and Disposal 29", {}], "6": ["3.6 Records; Reports; Audits 30", {}]}], "4": ["4. Diligence", {}], "5": ["5. Most Favored Customer", {}], "6": ["6. Governance", {"1": ["6.1 Joint Management Committee 31", {}], "2": ["6.2 JRDC 33", {}], "3": ["6.3 JOC 34", {}], "4": ["6.4 Alliance Director 34", {}], "5": ["6.5 Limitations of Authority 34", {}], "6": ["6.6 Expenses 35", {}], "7": ["6.7 Lifetime 35", {}]}], "7": ["7. Regulatory", {}], "8": ["8. Payment", {"1": ["8.1 FTE Funding 35", {}], "2": ["8.2 Molecular Information Platform Program Fees 35", {}], "3": ["8.3 Immunotherapy Testing Platform Development Budget and Fees 36", {}], "4": ["8.4 ctDNA Platform Financial Terms 37", {}], "5": ["8.5 CDx Development Financial Terms 38", {}], "6": ["8.6 General Terms 38", {}], "7": ["8.7 Disclosure of Payments 39", {}]}], "9": ["9. Accounting and reporting", {"1": ["9.1 Timing of Payments 39", {}], "2": ["9.2 Late Payment 39", {}], "3": ["9.3 Method of Payment 39", {}]}], "10": ["10. Taxes", {}], "11": ["11. Auditing", {"1": ["11.1 Right to Audit 40", {}], "2": ["11.2 Audit Reports 41", {}], "3": ["11.3 Over or Underpayment 41", {}], "4": ["11.4 Duration of Audit Rights 41", {}]}], "12": ["12. Intellectual Property", {"1": ["12.1 Ownership of Inventions, data and results 41", {}], "2": ["12.2 German Statute on Employees Inventions 43", {}], "3": ["12.3 Prosecution and Maintenance of Patent Rights Claiming FMI Inventions 43", {}], "4": ["12.4 Prosecution and Maintenance of Roche Foreground Patent Rights and Joint Patent Rights 44", {}], "5": ["12.5 Joint Patent Team 44", {}], "6": ["12.6 CREATE Act 44", {}], "7": ["12.7 Infringement 44", {}], "8": ["12.8 Defense 46", {}], "9": ["12.9 Common Interest Disclosures 46", {}]}], "13": ["13. Representations and Warranties", {"1": ["13.1 Mutual Representations and Warranties 47", {}], "2": ["13.2 Activities 48", {}], "3": ["13.3 Safety Data 48", {}], "4": ["13.4 Third Party Patent Rights 48", {}], "5": ["13.5 Inventors 48", {}], "6": ["13.6 Grants 48", {}], "7": ["13.7 Ownership and Validity of Know-How 48", {}], "8": ["13.8 Data Protection (Privacy) and Security 48", {}], "9": ["13.9 No Other Representations 50", {}]}], "14": ["14. Indemnification", {"1": ["14.1 Indemnification by Roche 50", {}], "2": ["14.2 Indemnification by FMI 51", {}], "3": ["14.3 Procedure 51", {}]}], "15": ["15. Liability", {}], "16": ["16. Obligation Not to Disclose Confidential Information", {"1": ["16.1 Non-Use and Non-Disclosure 51", {}], "2": ["16.2 Permitted Disclosure 52", {}], "3": ["16.3 Press Releases 52", {}], "4": ["16.4 Publications 52", {}], "5": ["16.5 Commercial Considerations 53", {}]}], "17": ["17. Term and Termination", {"1": ["17.1 Commencement and Term 53", {}], "2": ["17.2 Termination 53", {}], "3": ["17.2 Termination for Breach 53", {}], "4": ["17.2 Insolvency 53", {}], "5": ["17.2 Termination by Roche without Cause 54", {}], "6": ["17.2 Termination by Roche for Frustration of Purpose 54", {}], "7": ["17.3 Consequences of Termination 54", {}], "8": ["17.3 Termination in General 54", {}], "9": ["17.3 Termination by FMI for Breach by Roche or Roches Insolvency; Termination by Roche Without Cause or for Frustration of Purpose 54", {}], "10": ["17.3 Termination by Roche for Breach by FMI or FMI Insolvency 56", {}], "11": ["17.3 Direct License 57", {}], "12": ["17.4 Other Obligations 57", {}], "13": ["17.5 Survival 57", {}]}], "18": ["18. Bankruptcy", {}], "19": ["19. Miscellaneous", {"1": ["19.1 Governing Law 58", {}], "2": ["19.2 Disputes 58", {}], "3": ["19.3 Arbitration 58", {}], "4": ["19.4 Assignment 59", {}], "5": ["19.5 Debarment and Exclusion 59", {}], "6": ["19.6 Independent Contractor 60", {}], "7": ["19.7 Unenforceable Provisions and Severability 60", {}], "8": ["19.8 Waiver 60", {}], "9": ["19.9 Appendices 60", {}], "10": ["19.10 Entire Understanding 61", {}], "11": ["19.11 Amendments 61", {}], "12": ["19.12 Invoices 61", {}], "13": ["19.13 Notice 61", {}]}], "20": ["1.1 Affiliate", {}], "21": ["1.2 Agreement", {}], "22": ["1.3 Agreement Term", {}], "23": ["1.4 [***] ctDNA [***]", {}], "24": ["1.5 Applicable Law", {}], "25": ["1.6 Approved Assay", {}], "26": ["1.7 Background IP", {}], "27": ["1.8 Business Day", {}], "28": ["1.9 Calendar Half", {}], "29": ["1.10 Calendar Quarter", {}], "30": ["1.11 Calendar Year", {}], "31": ["1.12 CDx", {}], "32": ["1.13 CDx Development Program", {}], "33": ["1.14 CLIA", {}], "34": ["1.15 Clinical Study", {}], "35": ["1.16 Commercially Reasonable Efforts", {}], "36": ["1.17 Confidential Information", {}], "37": ["1.18 Control", {}], "38": ["1.19 Cover", {}], "39": ["1.20 ctDNA", {}], "40": ["1.21 ctDNA Assay", {}], "41": ["1.22 ctDNA Platform", {}], "42": ["1.23 ctDNA Platform Development Program", {}], "43": ["1.24 ctDNA Working Group", {}], "44": ["1.25 Data Security Breach", {}], "45": ["1.26 Effective Date", {}], "46": ["1.27 Excepted Activities", {}], "47": ["1.28 Excluded Patent Rights", {}], "48": ["1.29 FDA", {}], "49": ["1.30 FDCA", {}], "50": ["1.31 FMI Background IP Patent Rights", {}], "51": ["1.32 FMI Decisions", {}], "52": ["1.33 FMI Development Costs", {}], "53": ["1.34 FMI Know-How", {}], "54": ["1.35 FMI Foreground Patent Rights", {}], "55": ["1.36 FTE", {}], "56": ["1.37 FTE Rate", {}], "57": ["1.38 Handle", {}], "58": ["1.39 HSR", {}], "59": ["1.40 Immunotherapy Testing Platform Development Program", {}], "60": ["1.41 Immuno-Platform Working Group", {}], "61": ["1.42 Initiation", {}], "62": ["1.43 Insolvency Event", {}], "63": ["1.44 Invention", {}], "64": ["1.45 IUO", {}], "65": ["1.46 JMC", {}], "66": ["1.47 JOC", {}], "67": ["1.48 Joint Know-How", {}], "68": ["1.49 Joint Patent Rights", {}], "69": ["1.50 JOT", {}], "70": ["1.51 JRDC", {}], "71": ["1.52 Know-How", {}], "72": ["1.53 Molecular Information Platform Program", {}], "73": ["1.54 Molecular Information Platform Working Group", {}], "74": ["1.55 Party", {}], "75": ["1.56 Patent Rights", {}], "76": ["1.57 Performance Specifications", {}], "77": ["1.58 Personal Data", {}], "78": ["1.59 Phase I Study", {}], "79": ["1.60 Phase II Study", {}], "80": ["1.61 Phase III Study", {}], "81": ["1.62 PMA", {}], "82": ["1.63 Quality Standards", {}], "83": ["1.64 R&D Plan", {}], "84": ["1.65 Regulatory Approval", {}], "85": ["1.66 Regulatory Authority", {}], "86": ["1.67 Roche Background IP Patent Rights", {}], "87": ["1.68 Roche Group", {}], "88": ["1.69 Roche Know-How", {}], "89": ["1.70 Roche Foreground Patent Rights", {}], "90": ["1.71 ROW Territory", {}], "91": ["1.72 RUO", {}], "92": ["1.73 Study Data", {}], "93": ["1.74 Sublicensee", {}], "94": ["1.75 Territory", {}], "95": ["1.76 Third Party", {}], "96": ["1.77 US", {}], "97": ["1.78 US$", {}], "98": ["1.79 Work Stream", {}], "99": ["1.80 Additional Definitions", {}], "100": ["2.1 Licenses", {}], "101": ["2.1 .1 Research and Development Cross License", {}], "102": ["2.1 .2 Molecular Information Platform Licenses", {}], "103": ["2.1 .3 Immunotherapy Testing Platform Licenses", {}], "104": ["2.1 .4 ctDNA Licenses", {}], "105": ["2.1 .5 CDx Development Program", {}], "106": ["2.2 Sublicense", {}], "107": ["2.3 Right to Subcontract", {}], "108": ["3.1 Molecular Information Platform Program", {}], "109": ["3.1 .1 Scope", {}], "110": ["3.1 .2 Molecular Information Platform Working Group", {}], "111": ["3.1 .3 Task Orders", {}], "112": ["3.1 .4 Sample Profiling and Reserved Capacity", {}], "113": ["3.1 .5 Forecasting and Binding Orders", {}], "114": ["3.1 .6 Samples, Sample Results, Web-Portal", {}], "115": ["3.1 .7 Clinical Reports", {}], "116": ["3.1 .8 Database Insights", {}], "117": ["3.1 .9 Molecular Information Database Access", {}], "118": ["3.1 .10 Duration and Extension", {}], "119": ["3.2 Immunotherapy Testing Platform Development Program", {}], "120": ["3.2 .1 Scope", {}], "121": ["3.2 .2 Immuno-Platform Working Group", {}], "122": ["3.2 .3 R&D Plan", {}], "123": ["3.2 .4 Responsibilities of the Parties", {}], "124": ["3.2 .5 Budget", {}], "125": ["3.2 .6 Duration", {}], "126": ["3.2 .7 Extension", {}], "127": ["3.2 .8 Exclusivity", {}], "128": ["3.2 .9 Excepted Activities", {}], "129": ["3.3 ctDNA Platform Development Program", {}], "130": ["3.3 .1 Scope", {}], "131": ["3.3 .2 Working Group", {}], "132": ["3.3 .3 R&D Plan", {}], "133": ["3.3 .4 Responsibilities of the Parties", {}], "134": ["3.3 .5 Budget", {}], "135": ["3.3 .6 Duration", {}], "136": ["3.3 .7 Extension", {}], "137": ["3.3 .9 Commercialization", {}], "138": ["3.4 CDx Development Program", {}], "139": ["3.4 .1 Scope", {}], "140": ["3.4 .2 Working Group", {}], "141": ["3.4 .3 R&D Plan", {}], "142": ["3.4 .4 Responsibilities of the Parties", {}], "143": ["3.4 .5 Budget", {}], "144": ["3.4 .6 Duration", {}], "145": ["3.4 .7 Extension", {}], "146": ["3.4 .8 Continuing Obligations", {}], "147": ["3.4 .9 Commercialization", {}], "148": ["3.5 Samples, Handling and Disposal", {}], "149": ["3.5 .1 Samples", {}], "150": ["3.5 .2 Sample Handling and Disposal", {}], "151": ["3.6 Records; Reports; Audits", {}], "152": ["3.6 .1 Progress Reports", {}], "153": ["3.6 .2 Research Records", {}], "154": ["3.6 .3 Regulatory Inspections and Audit", {}], "155": ["6.1 Joint Management Committee", {}], "156": ["6.1 .1 Members", {}], "157": ["6.1 .2 Responsibilities of the JMC", {}], "158": ["6.1 .3 Meetings", {}], "159": ["6.1 .4 Minutes", {}], "160": ["6.1 .5 Decisions", {}], "161": ["6.1 . 5.1 Decision Making Authority", {}], "162": ["6.1 . 5.2 ctDNA Platform", {}], "163": ["6.1 . 5.3 Consensus; Good Faith", {}], "164": ["6.1 . 5.4 Failure to Reach Consensus", {}], "165": ["6.1 . 5.5 Escalation", {}], "166": ["6.1 .6 Information Exchange", {}], "167": ["6.1 .7 Subcommittees and Joint Operational Teams", {}], "168": ["6.2 JRDC", {}], "169": ["6.2 .1 Responsibilities of the JRDC", {}]}